JNJ
Two-year data, not a one-night stand
Johnson & Johnson is back with fresh Phase 3 data for ICOTYDE (icotrokinra), its oral IL-23R-targeted peptide for plaque psoriasis. The headline: the drug showed durable skin clearance through 2 years in the ICONIC-TOTAL study, which is exactly the kind of long-haul evidence pharma investors like to see before they start daydreaming about blockbuster math.
And this wasn’t just about the broad psoriasis crowd. J&J says 60% of patients with scalp psoriasis and 89% of patients with genital psoriasis hit site-specific complete skin clearance at Week 112. In other words, the drug seems to be doing well in the awkward-to-treat, highly visible places where patients really notice whether a treatment is working.
Why investors should care
Psoriasis is one of those big pharma battlegrounds where efficacy, safety, and convenience all have to show up to the party. An oral therapy with durable results and a favorable safety profile can be a serious commercial weapon, especially if doctors start thinking of it as a first-line systemic option rather than a niche backup.
For J&J, this is part of a broader pipeline story: the company keeps trying to prove that its next wave of immunology drugs can carry some of the weight as older products mature. The more data ICOTYDE stacks up, the less it looks like a lab curiosity and the more it starts looking like a real contender.
Big picture: pharma stocks love a clean story, and long-duration efficacy data is about as clean as it gets. If ICOTYDE keeps delivering, J&J could have another meaningful growth engine on its hands.